Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037449 | 0.91 | KDM4E (0.53) | MTNR1AMTNR1BACACBKDM4EF13A1 | |
| SCHEMBL20249197 | 0.82 | KMT2A (0.47) | KDM4EPOLBL3MBTL1 | |
| SCHEMBL6788708 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BACACBKDM4EF13A1 | |
| SCHEMBL20037794 | 0.79 | MTNR1A (0.48) | MTNR1AMTNR1BACACBKDM4EF13A1 | |
| SCHEMBL18291730 | 0.79 | NAMPT (0.50) | MTNR1AMTNR1BACACBKDM4EF13A1 | |
| SCHEMBL20249198 | 0.78 | HSD17B10 (0.49) | KDM4EL3MBTL1 | |
| SCHEMBL20249202 | 0.77 | POLB (0.53) | POLB | |
| SCHEMBL20249204 | 0.77 | CA2 (0.43) | KDM4EPOLBL3MBTL1 | |
| SCHEMBL20249185 | 0.75 | CA2 (0.45) | KDM4EPOLBL3MBTL1 | |
| SCHEMBL10262595 | 0.75 | NFKB1 (0.51) | KDM4EPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | MTNR1A 2004/4885MTNR1B 1627/4885ACACB 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.